These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 7956451)

  • 1. Comparative in vitro activity of fleroxacin, two other quinolones and three board-spectrum beta-lactams using the E-Test.
    Sobottka I; Neumann S; Laufs R
    Chemotherapy; 1994; 40(5):293-8. PubMed ID: 7956451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
    McCarter YS; Mazens-Sullivan MF; Bartlett RC
    Chemotherapy; 1992; 38(5):308-18. PubMed ID: 1337507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
    Barry AL; Fuchs PC
    J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter study on the comparative in vitro activity of fleroxacin and three other quinolones: an interim report from 27 centers.
    Beskid G; Prosser BL
    Am J Med; 1993 Mar; 94(3A):2S-8S. PubMed ID: 8383919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of E-4868, a new fluoroquinolone with a 7-azetidin ring, compared with ciprofloxacin, ofloxacin and fleroxacin.
    Mirelis B; Navarro F; Miró E; Coll R; Xicota MA; Prats G
    Drugs Exp Clin Res; 1995; 21(4):129-38. PubMed ID: 8529525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of 310 nonfermentative gram-negative bacteria to aztreonam, carumonam, ciprofloxacin, ofloxacin and fleroxacin.
    Appelbaum PC; Spangler SK; Tamarree T
    Chemotherapy; 1988; 34(1):40-5. PubMed ID: 3127127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter in vitro comparative study of fluoroquinolones against 25,129 gram-positive and gram-negative clinical isolates.
    Prosser BL; Beskid G
    Diagn Microbiol Infect Dis; 1995 Jan; 21(1):33-45. PubMed ID: 7789095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in-vitro activities of trovafloxacin, ciproflaxacin, ofloxacin, and broad-spectrum beta-lactams against aerobe blood culture isolates.
    Seifert H
    Zentralbl Bakteriol; 1998 Dec; 288(4):509-18. PubMed ID: 9987189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter comparative study of the in vitro activity of fleroxacin and other antimicrobial agents.
    Markowitz SM; Williams DS; Hanna CB; Parker JL; Pierce MA; Steele JC
    Chemotherapy; 1995; 41(6):477-86. PubMed ID: 8529440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-resistance and cross-susceptibility between fluoroquinolone agents.
    Barry AL; Fuchs PC
    Eur J Clin Microbiol Infect Dis; 1991 Dec; 10(12):1013-8. PubMed ID: 1666360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro studies of fleroxacin (Ro 23-6240), a new trifluorinated quinolone derivative.
    Digranes A; Benonisen E; Salveson A; Zahm F
    Chemotherapy; 1988; 34(5):401-10. PubMed ID: 3141116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative in-vitro activity of Ro 23-6240, a new trifluorinated quinolone.
    Verbist L
    J Antimicrob Chemother; 1987 Sep; 20(3):363-72. PubMed ID: 3119552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative antimicrobial activity and spectrum of CP-99,219, a novel fluoroquinolone, tested against ciprofloxacin-resistant clinical isolates.
    Murphy SP; Cormican MG; Jones RN
    Ir J Med Sci; 1995; 164(4):271-3. PubMed ID: 8522427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams.
    Behra-Miellet J; Dubreuil L; Jumas-Bilak E
    Int J Antimicrob Agents; 2002 Nov; 20(5):366-74. PubMed ID: 12431872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in vitro antibacterial activity of ofloxacin and ciprofloxacin against some selected gram-positive and gram-negative isolates.
    Chau PY; Leung YK; Ng WW
    Infection; 1986; 14 Suppl 4():S237-9. PubMed ID: 3469153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial activity evaluations of two new quinolones, PD127391 (CI-960 and AM-1091) and PD131628.
    Barrett MS; Jones RN; Erwin ME; Johnson DM; Briggs BM
    Diagn Microbiol Infect Dis; 1991; 14(5):389-401. PubMed ID: 1665774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens.
    Naber KG; Well M; Hollauer K; Kirchbauer D; Witte W
    Chemotherapy; 1998; 44(2):77-84. PubMed ID: 9551236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
    Malmborg AS; Ahlén S
    Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the mechanism of action and resistance of two new fluoroquinolones, rufloxacin and MF961 with those of ofloxacin and fleroxacin in gram-negative and gram-positive bacteria.
    Piddock LJ; Panchal S; Norte V
    J Antimicrob Chemother; 1993 Jun; 31(6):855-63. PubMed ID: 8395493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in-vitro activity of fleroxacin against 480 nosocomial isolates.
    Sofianou D; Frantzidou F; Tsakris A
    J Chemother; 1994 Dec; 6(6):399-403. PubMed ID: 7699427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.